TriSalus beats Q4 revenue estimates, reaffirms 2026 guidance

TriSalus Life Sciences

05/03/2026 21:09

Overview

Oncology company's Q4 revenue rose 60% yr/yr, beating analyst expectations

Company reaffirmed 2026 revenue guidance of $60-62 mln

Company raised $46 mln in gross proceeds from recent public offering

Outlook

TriSalus reaffirms 2026 revenue guidance of $60-62 mln

Company plans to expand sales and commercial organizations in 2026

Company to invest in clinical studies to demonstrate PEDD value

Result Drivers

TRINAV SALES - Revenue growth driven by increased TriNav unit sales within liver applications

EXPANDED PRODUCT SUITE - Expansion of TriNav platform across multiple indications beyond the liver

Company press release: ID:nBw8BjsZKa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$13.21 mln
$12.76 mln (5 Analysts)
Q4 Gross Profit
$11.44 mln
Q4 Income from Operations
-$3.27 mln
Q4 Pretax Profit
-$9.75 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for TriSalus Life Sciences Inc is $12.00, about 140% above its March 4 closing price of $5.00

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)